Volume 2.35 | Sep 6

Hematopoiesis News 2.35, September 6, 2011
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
Researchers Successfully Perform First Injection of Cultured Red Blood Cells in Human Donor
For the first time, researchers have successfully injected cultured red blood cells created from human hematopoietic stem cells into a human donor. [Press release from the American Society of Hematology discussing online prepublication in Blood] Press Release | Abstract

PUBLICATIONS (Ranked by Impact Factor of the Journal)


Heritable GATA2 Mutations Associated with Familial Myelodysplastic Syndrome and Acute Myeloid Leukemia
Scientists report the discovery of GATA2 as a new myelodysplastic syndrome-acute myeloid leukemia predisposition gene. [Nat Genet] Abstract | Press Release

Mutations in GATA2 Cause Primary Lymphedema Associated with a Predisposition to Acute Myeloid Leukemia (Emberger Syndrome)
Researchers report an allelic series of eight mutations in GATA2 underlying Emberger syndrome, an autosomal dominant primary lymphedema associated with a predisposition to acute myeloid leukemia. [Nat Genet] Abstract

AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias
AKT activation is associated with many malignancies, where AKT acts, in part, by inhibiting FOXO tumor suppressors. Investigators show a converse role for AKT/FOXOs in acute myeloid leukemia. [Cell] Abstract

p57Kip2 and p27Kip1 Cooperate to Maintain Hematopoietic Stem Cell Quiescence through Interactions with Heat Shock Cognate Protein 70
In this study, investigators report that cell cycle entry proceeded normally in hematopoietic stem cells null for cyclin-dependent kinase inhibitor p57 due to compensatory upregulation of p27. [Cell Stem Cell] Abstract

p57 Is Required for Quiescence and Maintenance of Adult Hematopoietic Stem Cells
Results suggest that, among Cip/Kip family cyclin-dependent kinase inhibitors, p57 plays a predominant role in the quiescence and maintenance of adult hematopoietic stem cells. [Cell Stem Cell] Abstract

Cooperation Between Both Wnt/β-Catenin and PTEN/PI3K/Akt Signaling Promotes Primitive Hematopoietic Stem Cell Self-Renewal and Expansion
Using a hematopoietic stem and progenitor cell-specific conditional induction line, researchers generated a compound genetic model bearing both Pten deletion and β-catenin activation. [Genes Dev] Abstract

Site-Specific Gene Correction of a Point Mutation in Human iPS Cells Derived from an Adult Patient with Sickle Cell Disease
Here scientists report a homologous recombination based approach to precisely correct the sickle cell disease mutation in patient-derived induced pluripotent stem cell (iPSC) with two mutated beta-globin alleles. [Blood] Abstract


A Two-Step Approach to Myeloablative Haploidentical Stem Cell Transplantation: A Phase I/II Trial Performed with Optimized T-Cell Dosing
Investigators developed a 2 step myeloablative approach to haploidentical hematopoietic stem cell transplantation (HSCT) in which 27 patients conditioned with total body irradiation were given a fixed dose of donor T cells (HSCT step 1), followed by cyclophosphamide (CY) for T cell tolerization. A CD34 selected HSC product (HSCT step 2) was infused after CY. [Blood] Abstract | Press Release

Gene Mutation Patterns and Their Prognostic Impact in a Cohort of 1,185 Patients with Acute Myeloid Leukemia
To evaluate the prognostic value of genetic mutations for acute myeloid leukemia (AML) patients, researchers examined the gene status for both fusion products such as AML1 (CBFα)-ETO, CBFβ-MYH11, PML-RARα and MLL rearrangement as a result of chromosomal translocations and mutations in genes including FLT3, C-KIT, N-RAS, NPM1, CEBPA, WT1, ASXL1, DNMT3A, MLL, IDH1, IDH2 and TET2 in 1,185 AML patients. [Blood] Abstract

Azacitidine for Treatment of Imminent Relapse in MDS or AML Patients After Allogeneic HSCT: Results of the RELAZA Trial
This study evaluated azacitidine as treatment of minimal residual disease determined by a sensitive donor chimerism analysis of CD34+ blood cells to pre-empt relapse in patients with CD34+ myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT). [Leukemia] Abstract



CIRM Commits $1.8 Million to Build Stem Cell Teams, Accelerate New Therapies
The California Institute for Regenerative Medicine (CIRM) approved funding $1.8 million to support 19 researchers in their effort to assemble competitive teams to develop applications for the Disease Team Therapy Development Awards, which will be due in winter 2012. [California Institute for Regenerative Medicine] Press Release

Cyclacel Announces Commencement of Investigator-Initiated Phase II Trial of Sapacitabine in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Hematological Malignancies and 11q22-23 Deletion

Cyclacel Pharmaceuticals, Inc. announced that the first patient has been dosed in an investigator-initiated, translational, Phase II clinical study at The University of Texas MD Anderson Cancer Center. [Cyclacel Pharmaceuticals, Inc.] Press Release

Skyline Diagnostics and Clavis Pharma to Collaborate on Patient Selection Biomarker Discovery for Leukemia Drug Elacytarabine
Skyline Diagnostics B.V. and Clavis Pharma ASA disclosed signing a research agreement. Under this agreement, Skyline will investigate gene expression biomarkers for selection of individual acute myeloid leukemia (AML) patients that may benefit from a new AML drug in development at Clavis. [Skyline Diagnostics B.V.] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW International Conference on Biotechnology and Pharmaceutical Sciences (ICBPS’2011)
October 7-8, 2011
Pattaya, Thailand

NEW 5th Advances in Stem Cell Discovery and Development
October 19-21, 2011
San Diego, United States 

Visit our events page to see a complete list of events in the hematopoietic community

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Contract Assay Service Technologist (STEMCELL Technologies)

Research and Development Technologist (STEMCELL Technologies)

Postdoctoral Position (Izmir Katip Celebi University)

Postdoctoral Positions in Stem Cells and Immunology (University of Connecticut)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us